Jazz Pharmaceuticals (JAZZ) Assets Average (2011 - 2026)

Jazz Pharmaceuticals' Assets Average history runs 16 years deep, the most recent figure standing at $11.8 billion for Q1 2026.

• On a quarterly basis, Assets Average changed 0.12% year-over-year to $11.8 billion in Q1 2026; TTM through Mar 2026 was $11.8 billion, a 0.12% change from a year earlier, with the FY2025 full-year figure at $11.8 billion, up 1.14% from the prior year.
• Assets Average grew to $11.8 billion in Q1 2026 per JAZZ's latest filing, from $11.5 billion in the prior quarter.
• Across five years, Assets Average topped out at $12.1 billion in Q4 2024 and bottomed at $10.6 billion in Q4 2022.
• The 5-year median for Assets Average is $11.3 billion (2024), against an average of $11.4 billion.
• Biggest YoY gain for Assets Average was 81.06% in 2022; the steepest drop was 15.98% in 2022.
• Year by year, Assets Average stood at $10.6 billion in 2022, then advanced by 6.49% to $11.3 billion in 2023, then increased by 7.39% to $12.1 billion in 2024, then dropped by 5.16% to $11.5 billion in 2025, then grew by 2.19% to $11.8 billion in 2026.
• Per Business Quant, the three latest JAZZ Assets Average figures stand at $11.8 billion (Q1 2026), $11.5 billion (Q4 2025), and $11.2 billion (Q3 2025).